DDInter68 DDInter1376
A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Amiloride {u} (Compound) treats {v} (Disease) hypertension
Amiloride {u} (Compound) binds {v} (Gene) SLC22A1
Amiloride {u} (Compound) is included by {v} (Pharmacologic Class) Increased Diuresis
Amiloride {u} (Compound) causes {v} (Side Effect) Angina pectoris
Amiloride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doxycycline
Amiloride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Oxytetracycline
Amiloride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Danaparoid
Amiloride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Amiloride {u} may lead to a major life threatening interaction when taken with {v} Potassium chloride
Amiloride (Compound) treats hypertension (Disease)
Amiloride (Compound) binds SLC22A1 (Gene)
Amiloride (Compound) is included by Increased Diuresis (Pharmacologic Class)
Amiloride (Compound) causes Angina pectoris (Side Effect)
Amiloride may cause a minor interaction that can limit clinical effects when taken with Doxycycline
Amiloride may cause a minor interaction that can limit clinical effects when taken with Oxytetracycline
Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Danaparoid
Amiloride may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin
Amiloride may lead to a major life threatening interaction when taken with Potassium chloride